What Is the Alternative to Ozempic for Weight Loss?

Last reviewed: July 2, 2026

Last updated: July 2, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The question contains a premise worth correcting before answering it: Ozempic is not approved for weight loss in the first place. Per its FDA labeling, Ozempic is indicated to improve glycemic control in adults with type 2 diabetes, to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained kidney function decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. There is no weight-management indication and no BMI criterion anywhere in it. So the real question is not "what replaces Ozempic" but "what is actually approved for the job people assume Ozempic does" — and there are seven answers.

The Approved Options, According to NIH

The National Institute of Diabetes and Digestive and Kidney Diseases maintains a current list of prescription medications approved to treat overweight and obesity. For long-term use it names orlistat (Xenical, and the lower-dose over-the-counter Alli), phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), liraglutide (Saxenda), semaglutide (Wegovy), tirzepatide (Zepbound), and setmelanotide (IMCIVREE) for specific rare genetic conditions.

NIDDK also states the general eligibility framing clinicians work from: a medication may be prescribed for an adult with a BMI of 30 or greater, or a BMI of 27 or greater accompanied by weight-related health problems such as high blood pressure or type 2 diabetes. That is the criterion people are usually thinking of when they ask about Ozempic — it belongs to the weight-management drugs, not to Ozempic.

The Closest Answer Is the Same Molecule Under a Different Brand

Semaglutide is the active ingredient in Ozempic. It is also the active ingredient in Wegovy, which is the semaglutide product that actually holds weight-management approval. Wegovy injection is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity, and in adults with overweight plus at least one weight-related comorbid condition. It additionally carries a cardiovascular risk reduction indication and, more recently, an indication in noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis.

The evidence behind that approval came from a dedicated obesity program. In STEP 1, 1,961 adults without diabetes received once-weekly semaglutide 2.4 mg or placebo for 68 weeks alongside lifestyle intervention; mean body weight change was −14.9% versus −2.4%, and 50.5% of the semaglutide group achieved reductions of 15% or more compared with 4.9% on placebo.

Tirzepatide Is the Other Injectable Route

Zepbound is tirzepatide, a dual GIP and GLP-1 receptor agonist rather than a GLP-1 receptor agonist alone. Its labeling indicates it, in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity.

Mounjaro contains the same molecule but is approved only for glycemic control in type 2 diabetes. The Mounjaro-to-Zepbound relationship exactly mirrors the Ozempic-to-Wegovy relationship, which is why the two pairs generate the same recurring confusion.

There Is Now Direct Head-to-Head Evidence

Until recently, comparisons between semaglutide and tirzepatide relied on cross-trial inference. SURMOUNT-5 changed that. In this phase 3b open-label controlled trial, 751 adults with obesity but without type 2 diabetes were randomized to the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or the maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg), given subcutaneously once weekly for 72 weeks.

The least-squares mean percent weight change at week 72 was −20.2% with tirzepatide and −13.7% with semaglutide. Least-squares mean waist circumference change was −18.4 cm versus −13.0 cm. Gastrointestinal adverse events were the most common in both groups, mostly mild to moderate and concentrated during dose escalation.

A trial average is not a personal prediction. It says which arm did better on average; it does not say which arm suits one person's other conditions, medications, or tolerance.

Oral Options Now Exist

For people whose objection to Ozempic is the injection itself, the landscape changed twice in the past year. Semaglutide tablets for weight management were approved on December 22, 2025, supplied in 1.5 mg, 4 mg, 9 mg, and 25 mg and taken once daily on an empty stomach.

Separately, orforglipron — brand name Foundayo, initial U.S. approval 2026 — is a GLP-1 receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight plus at least one weight-related comorbid condition. It is taken orally once daily with or without food, and its labeled maximum dosage is 17.2 mg once daily. Unlike semaglutide, it is a non-peptide molecule, which is what makes the food-timing requirements less restrictive.

The Non-Incretin Alternatives Are Still Alternatives

The conversation has become so GLP-1-centric that the older approved drugs get overlooked, and for some people they are the better fit. Orlistat works in the gut to reduce dietary fat absorption. Qsymia combines phentermine, which lessens appetite, with topiramate. Contrave combines naltrexone and bupropion and may reduce hunger or promote earlier fullness. Saxenda is liraglutide, a GLP-1 receptor agonist given as a daily injection rather than a weekly one.

These differ in mechanism, approved age ranges, contraindications, and interaction profiles. Someone whose history makes topiramate or bupropion inappropriate does not have the same menu as someone without those constraints, which is precisely why the selection is a prescriber's job.

Where Compounded Semaglutide Sits

Compounded semaglutide is not on the list above, and it is important to be clear about why. The FDA states that compounded drugs are not FDA approved and that the agency does not review them for safety, effectiveness, or quality before marketing. A compounded preparation is dispensed by a licensed pharmacy against a prescription for an individual patient. It is not an approved generic of any brand, because no approved generic of these products exists.

The FDA has also warned specifically about semaglutide salt forms such as semaglutide sodium and semaglutide acetate, which it describes as different active ingredients than those used in the approved drugs, and about products sold online labeled "for research purposes" or "not for human consumption." Those are not alternatives; they are unapproved drugs sold outside the prescribing system.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

What is the closest alternative to Ozempic for weight loss?

Wegovy, because it contains the same active ingredient, semaglutide, and actually holds the weight-management indication that Ozempic lacks. Ozempic's labeled uses are all in type 2 diabetes: glycemic control, cardiovascular risk reduction, and kidney outcome risk reduction. If the goal is weight management specifically, Wegovy is the semaglutide product approved for that purpose in adults and in patients aged 12 and older.

Is Zepbound better than Wegovy?

In the SURMOUNT-5 head-to-head trial, 751 adults with obesity and without type 2 diabetes received maximum tolerated doses of either drug once weekly for 72 weeks. Least-squares mean weight change was −20.2% with tirzepatide versus −13.7% with semaglutide. That is a group average under one specific protocol, not a prediction for any individual, and it says nothing about which drug fits a particular person's health history.

Are there non-injectable alternatives?

Yes. Semaglutide tablets for weight management were approved on December 22, 2025 and are taken once daily on an empty stomach. Orforglipron, marketed as Foundayo, is an oral GLP-1 receptor agonist approved in 2026 for the same broad population and taken once daily with or without food. Orlistat, Qsymia, and Contrave are also oral and have been approved for long-term weight management for years.

Can I get a generic version of Ozempic?

No. There is no FDA-approved generic semaglutide product in the United States. Compounded semaglutide is sometimes described that way, but the FDA states compounded drugs are not FDA approved and are not reviewed by the agency for safety, effectiveness, or quality before marketing. A compounded preparation is made by a licensed pharmacy for an individual patient under a prescription, which is a different regulatory category entirely.

Why does my insurance cover Ozempic but not a weight-management drug?

Coverage usually follows the approved indication rather than the molecule. Ozempic's indications are diabetes-related, so it is adjudicated against a diabetes diagnosis. Weight-management products are adjudicated against obesity criteria, which many plans exclude or restrict through prior authorization. This is why two products containing the same active ingredient can be covered very differently for the same person.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.